Antares Pharma, Inc. (ATRS), relating to its proposed acquisition by Halozyme Therapeutics, Inc. Under the terms of the agreement, ATRS shareholders will receive $5.60 in cash per share they own
Antares Pharma, Inc. (ATRS), relating to its proposed acquisition by Halozyme Therapeutics, Inc. Under the terms of the agreement, ATRS shareholders will receive $5.60 in cash per share they own